The Evolving Role of Immunotherapy in the Treatment with Curative Purpose of Early, Intermediate and Advanced Stage Hepatocellular Carcinoma
Current Oncology · 20.08.2026 · 33 (8) · 492
DOI: 10.3390/curroncol33080492 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 20.08.2026. Verfasst von Anastasia D Karampa und 5 weiteren Autor:innen. Beteiligte Einrichtung: HPB Unit, Department of Surgery, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is frequently diagnosed at advanced stages, thereby limiting curative treatment options. Although interventions with curative intent, such as liver resection and ablation, are available, recurrence rates exceed 70%. Recent developments in HCC management have shifted the focus from conventional surgery and targeted therapies to immunotherapy. This review synthesizes current evidence on immunotherapy for curative purposes in HCC, including both neoadjuvant and adjuvant strategies. It evaluates completed and ongoing clinical trials of immune checkpoint inhibitors (ICIs), administered as monotherapy or in combination with anti-angiogenic agents or dual-checkpoint blockade. ICIs may transform the initial treatment paradigm for advanced HCC, although their applications remain in the investigational stage. Preliminary results from the IMbrave050 trial suggested that adjuvant immunotherapy following radical liver resection improves recurrence-free survival (RFS) in high-risk patients. However, the initially promising outcomes of the combination of atezolizumab and bevacizumab compared with active surveillance were not sustained in the median follow-up, and long-term survival results are awaited. Although several studies have demonstrated encouraging preliminary results, a clear survival benefit has not yet been established. Further studies are necessary to establish definitive conclusions. Immunotherapy has a pathophysiological basis and preliminary evidence to redefine HCC management across disease stages; its integration into pre- and post-operative strategies may increase resectability, reduce recurrence, and improve survival. Ongoing trials are expected to clarify its exact role.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HPB Unit, Department of Surgery, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
- Department of Pathology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
- Department of Gastroenterology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
ORCID-Profile: Evangelos G Baltagiannis, Nikolaos-Andreas T Anastasopoulos
Zitieren
APA
Karampa, A. D., Goussia, A., Baltagiannis, E. G., Anastasopoulos, N. T., Christodoulou, D. K., & Glantzounis, G. K. (2026). The Evolving Role of Immunotherapy in the Treatment with Curative Purpose of Early, Intermediate and Advanced Stage Hepatocellular Carcinoma. Current Oncology, 33(8), 492. https://doi.org/10.3390/curroncol33080492
Vancouver
Karampa AD, Goussia A, Baltagiannis EG, Anastasopoulos NT, Christodoulou DK, Glantzounis GK. The Evolving Role of Immunotherapy in the Treatment with Curative Purpose of Early, Intermediate and Advanced Stage Hepatocellular Carcinoma. Current Oncology. 2026;33(8):492. doi:10.3390/curroncol33080492
BibTeX
@article{Karampa2026,
author = {Karampa, Anastasia D and Goussia, Anna and Baltagiannis, Evangelos G and Anastasopoulos, Nikolaos-Andreas T and Christodoulou, Dimitrios K and Glantzounis, Georgios K},
title = {The Evolving Role of Immunotherapy in the Treatment with Curative Purpose of Early, Intermediate and Advanced Stage Hepatocellular Carcinoma},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {8},
pages = {492},
doi = {10.3390/curroncol33080492}
}
EUVIMED